A clinical trial has demonstrated a 71% pathological complete response rate in patients with resectable desmoplastic melanoma following treatment with neoadjuvant pembrolizumab, an anti-programmed cell death protein 1 therapy. The…
You can read the full story here: Neoadjuvant Pembrolizumab: 71% Response Rate in Resectable Desmoplastic Melanoma .